Clinical Trials

Carcinoma, Fallopian Tube Neoplasms

NCT03010150 2026-04-15

Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer

471 enrolled

CNSDermatologicGastrointestinalGenitourinarySarcoma

Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms

NCT04897321 2026-04-15

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Phase 1 Recruiting

48 enrolled

Adrenal Cortex Neoplasms, Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT05347212 2026-04-15

Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

30 enrolled

Carcinoma

NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Phase 1/2 Recruiting

37 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

NCT05232851 2026-04-14

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

20 enrolled 11 charts

Phase 3 Not yet recruiting

Carcinoma, Oropharyngeal Neoplasms

NCT07529262 2026-04-14

AspiRe HCC

890 enrolled

Carcinoma, Fibrosis, Liver Cirrhosis, Neoplasms

NCT04520711 2026-04-13

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Phase 1 Active not recruiting

24 enrolled

Carcinoma

NCT07511517 2026-04-09

BladMetrix

Active not recruiting

500 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Hypersensitivity

NCT05050162 2026-04-03

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Phase 2/3 Suspended

1,714 enrolled

Carcinoma, Oropharyngeal Neoplasms

NCT06532279 2026-04-03

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

98 enrolled

Phase 3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Stomatitis

NCT07441681 2026-04-03

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

454 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07257094 2026-03-31

Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Rehabilitation Following Nasal Skin Cancer

346 enrolled

Dermatologic

Carcinoma, Carcinoma, Basal Cell, Carcinoma, Squamous Cell

NCT07400263 2026-03-30

Evaluation of an EpCAM-Targeted Radiotracer in Epithelial Tumors

Phase NA Recruiting

30 enrolled

Phase 1/2 Active not recruiting

Carcinoma

NCT07501780 2026-03-30

RELI

Not yet recruiting

297 enrolled

Dermatologic

Carcinoma, Carcinoma, Basal Cell, Neoplasms, Neoplasms, Basal Cell

NCT04261855 2026-03-27

GoTHAM

19 enrolled

DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT07281768 2026-03-20

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

66 enrolled

Phase EARLY_PHASE1 Recruiting

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

NCT05065736 2026-03-19

Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer

4 enrolled

Adenocarcinoma, Carcinoma, Neoplasm Metastasis, Neoplasms

NCT06128343 2026-03-19

BACAP-2

1,500 enrolled

Adenocarcinoma, Carcinoma, Neoplasms

NCT03922776 2026-03-18

TILsOV

Phase NA Terminated

36 enrolled

Carcinoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06205836 2026-03-17

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

44 enrolled

Phase 1/2 Not yet recruiting

Adenocarcinoma, Carcinoma, Colorectal Neoplasms

NCT07411599 2026-03-12

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

28 enrolled

Phase NA Not yet recruiting

Colorectal Cancer, Hereditary Nonpolyposis, Type 6, Carcinoma, Colorectal Neoplasms

NCT06456411 2026-03-10

Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer

Phase NA Recruiting

410 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Carcinoma, Renal Cell

NCT07453706 2026-03-09

The Application of Sentire Surgical System Plus Patient Side Single Arm in Robotic Colorectal Surgery

12 enrolled

Carcinoma

NCT06868433 2026-03-04

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Phase 1 Recruiting

40 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT06806930 2026-03-03

Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)

90 enrolled

Breast

Breast Neoplasms, Carcinoma, Neoplasms

NCT02574728 2026-03-02

AflacST1502

Phase NA Active not recruiting

46 enrolled

CNSMyeloidSarcoma

Brain Neoplasms, Carcinoma, Ependymoma, Histiocytosis, Langerhans-Cell, Medulloblastoma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT06595498 2026-03-02

Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer

130 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05063916 2026-02-27

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

18 enrolled

Carcinoma, Uterine Cervical Neoplasms

NCT05014776 2026-02-24

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

17 enrolled 8 charts

Phase 1 Not yet recruiting

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT07430202 2026-02-24

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

27 enrolled

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT07408635 2026-02-13

IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer

GastrointestinalHead & Neck

43 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03993353 2026-02-12

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

Phase 2 Completed

7 enrolled 14 charts

Pyridoxine-dependent epilepsy, Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms

NCT06027086 2026-02-12

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Phase 1/2 Recruiting

27 enrolled

Fibrolamellar hepatocellular carcinoma, Carcinoma

NCT06636734 2026-02-11

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

28 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT00349830 2026-02-10

Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

2,000 enrolled

Adenocarcinoma, Carcinoma, Neoplasms

NCT07365124 2026-01-26

MRinRT

Not yet recruiting

165 enrolled

CNSGastrointestinal

Carcinoma, Esophageal Neoplasms, Glioblastoma, Neoplasms, Neurologic Manifestations, Pancreatic Neoplasms, Stomach Neoplasms

NCT04429490 2026-01-21

PESTIPAC

Phase NA Completed

56 enrolled

Phase 3 Enrolling by invitation

Carcinoma

NCT07332611 2026-01-12

PROTEOMASH

Not yet recruiting

30 enrolled

Carcinoma, Fatty Liver

NCT07311057 2026-01-06

Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy

20 enrolled

Phase NA Active not recruiting

Carcinoma, Carcinoma, Squamous Cell

NCT04124198 2025-12-31

QoLATI

138 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, DNA Virus Infections, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Otorhinolaryngologic Diseases, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Papillomavirus Infections

NCT06612827 2025-12-24

OCAPI

20 enrolled

Carcinoma

NCT05520281 2025-12-15

ORPHYS

Phase NA Completed

24 enrolled

Necrophobia, Mental Disorders, Carcinoma, Neoplasms

NCT05917106 2025-12-11

Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)

450 enrolled

Genitourinary

Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms

NCT06564623 2025-12-05

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Phase 1 Recruiting

25 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

NCT06676527 2025-12-05

Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma